^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GnRH antagonist

    Related drugs:
    3d
    Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report. (PubMed, Front Med (Lausanne))
    The patient had undergone laparoscopic radical prostatectomy 5 years prior and received intermittent postoperative endocrine therapy with leuprorelin acetate and bicalutamide...Following a change in the endocrine therapy regimen to rezvilutamide combined with degarelix, the patient's hematuria significantly improved. This case highlights the critical importance of rigorous postoperative surveillance and timely, standardized endocrine therapy in prostate cancer management. It also contributes to the limited literature on visceral metastases in castration-sensitive prostate cancer (HSPC) and underscores the need for further exploration of optimal treatment strategies for advanced metastatic disease.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    bicalutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide)
    6d
    ELARIS EM-COC: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain (clinicaltrials.gov)
    P3, N=800, Active, not recruiting, AbbVie | Trial completion date: Jun 2030 --> Jul 2027 | Trial primary completion date: Mar 2029 --> Jul 2027
    Trial completion date • Trial primary completion date
    7d
    The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=110, Recruiting, Main Line Health | Trial completion date: Aug 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Orgovyx (relugolix)
    7d
    A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov)
    P3, N=266, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Trial completion date: Jun 2029 --> Jul 2028 | Trial primary completion date: Oct 2028 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    Cetrotide (cetrorelix)
    13d
    Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial (clinicaltrials.gov)
    P2, N=50, Recruiting, Sean Sachdev | Trial primary completion date: Nov 2028 --> Nov 2030
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    enzalutamide • Orgovyx (relugolix)
    14d
    Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (clinicaltrials.gov)
    P3, N=97, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting | N=297 --> 97 | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Mar 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    21d
    Debio 4228-201: A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Debiopharm International SA | Trial primary completion date: Dec 2026 --> Jun 2026 | Trial completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    1m
    SERENE: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (clinicaltrials.gov)
    P3, N=1164, Completed, Sumitomo Pharma Switzerland GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    Orgovyx (relugolix)
    2ms
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Recruiting, Jose Pablo Leone | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    2ms
    The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University Hospital, Geneva | Trial completion date: Dec 2026 --> Mar 2027
    Trial completion date
    2ms
    Triplet therapy combined with robot-assisted cytoreductive prostatectomy in high-volume metastatic prostate cancer: a prospective, multicentre, randomized controlled trial (ChiCTR2600121819)
    P=N/A, N=88, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    docetaxel • Firmagon (degarelix)
    2ms
    Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Orgovyx (relugolix)